Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Lymphoid 1Gynecologic 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1

Conditions

Wilms Tumor 1Sarcoma, Ewing 1Ovarian Neoplasms 1Osteosarcoma 1Neuroblastoma 1Melanoma 1Lymphoma, Non-Hodgkin 1Hepatoblastoma 1Endometrial Neoplasms 1Desmoid Tumors 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1

Interventions

X-Rays 6Specimen Handling 6Cyclophosphamide 6Phantoms, Imaging 5Magnetic Resonance Spectroscopy 4fludarabine 3Nuclear Medicine Department, Hospital 3Doxorubicin 3Biopsy 3ulixertinib 2tipifarnib 2selpercatinib 2mifamurtide 2ivosidenib 2fludarabine phosphate 2ensartinib 2cabozantinib 2Methotrexate 2Mesna 2Ifosfamide 2Gemcitabine 2Cisplatin 2trastuzumab deruxtecan 1tazemetostat 1talazoparib 1selinexor 1pembrolizumab 1pazopanib 1palbociclib 1olaparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Osteosarcoma × Bone Density × 30 days × Clear all
NCT04851119 2026-05-05

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Children's Oncology Group

Phase 1/2 Recruiting
147 enrolled
CNSDermatologicGastrointestinalGenitourinaryGynecologicLymphoidSarcoma

Carcinoma, Hepatocellular, Lymphoma, Non-Hodgkin, Melanoma, Wilms Tumor, Neuroblastoma, Ovarian Neoplasms, Sarcoma, Ewing, Osteosarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Hepatoblastoma, Desmoid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡